We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Cerys
Pennington
cpenning@liverpool.ac.uk
Mrs
Anita
Hanson
anita.hanson@liverpool.ac.uk
Matthew
Harding
matt.harding@cpft.nhs.uk
Illida
Nawi
illida.nawi@rlbuht.nhs.uk
Emily
Staunton
Emily.Staunton@liverpoolft.nhs.uk
Prof
Munir
Pirmohamed
munirp@liverpool.ac.uk
Gill
Rees
Gill.Rees@liverpoolft.nhs.uk
Illida
Nawi
illida.nawi@rlbuht.nhs.uk
Complications of surgical and medical care, not elsewhere classified
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Adverse drug reactions (ADR's) are a common cause of drug-related morbidity and may account for about 6.5% of all hospital admissions. A meta-analysis of studies performed in the USA has shown that ADRs may be the fourth commonest cause of death. ADRs are also a significant impediment to drug development, and a significant cause of drug withdrawal. The purpose of this research is to (a) identify patients with different types of adverse drug reactions; (b) using DNA obtained from blood or Saliva samples from these patients, identify genetic factors which predispose to adverse reactions. The net effect of our research will be the development of genetic tests which can help in predicting individual susceptibility to adverse reactions prior to the medication's administration. Patients with a pre-disposition to reacting adversely can be prescribed alternative medication of monitored more closely during their treatment. This will reduce the harm for patients and save valuable resources for the NHS.
We aim to recruit 250 cases for each reaction for a period of eight years throughout multiple sites in the UK. Specific adverse drug reactions we are looking at include:
- Statin induced myotoxicity, characterised by high CK
- Severe hypersensitivity reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
- Anaphylaxis induced by NMBA anaesthetics
- ACE inhibitor or ARB induced angioedema
- Taxane hypersensitivity
- Chemotherapy induced peripheral neuropathy
- Bleomycin induced lung toxicity
- Clozipine induced agranulocytosis or neutropenia
- Bisphosphonate-related osteonecrosis of the jaw
- Tenofovir associated renal injury
- Serious bleeds induced by warfarin or other anticoagulants
Arms for
Dihydropyrimidine Dehydrogenase (DPYD)
Glaucoma
Anthracycline of Induced Cardiotoxicity (ACT)
are now open on the study.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Not Specified;
You can take part if:
You may not be able to take part if:
> Patient unwilling to take part < br / > > Patient is, in the opinion of the Investigator, not suitable to participate in the study. < br / > > Unable to obtain written informed consent < br / > > Unable to nominate a consultee for patients who lack capacity (Only applies to NHS sites in England, which are set up for this process)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Matthew
Harding
matt.harding@cpft.nhs.uk
Prof
Munir
Pirmohamed
munirp@liverpool.ac.uk
Mrs
Anita
Hanson
anita.hanson@liverpool.ac.uk
Illida
Nawi
illida.nawi@rlbuht.nhs.uk
Cerys
Pennington
cpenning@liverpool.ac.uk
Gill
Rees
Gill.Rees@liverpoolft.nhs.uk
Illida
Nawi
illida.nawi@rlbuht.nhs.uk
Emily
Staunton
Emily.Staunton@liverpoolft.nhs.uk
The study is sponsored by University of Liverpool and funded by DEPARTMENT OF HEALTH AND SOCIAL CARE; European Commission; Medical Research Council (MRC); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 8630
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
